ANALYSIS OF SIDE EFFECTS AND DISADVANTAGES OF ANTI-INFLAMMATORY DRUGS RELATED TO THEIR USE
Abstract
The long-term effects of non-steroidal anti-inflammatory medicines (NSAIDs) on the development of symptoms and joint structural degradation in knee diseases are investigated in this study. Many people with arthritic disorders use non-steroidal anti-inflammatory medications (NSAIDs) both immediately as analgesics and chronically to reduce pain and inflammation. The suppression of the cyclooxygenase (COX) enzyme is the cause of both the positive and negative effects of NSAIDs. Depending on how selective they are for COX inhibition, NSAIDs are categorized as either non-selective or COX-2-selective inhibitors (COXIBS). Nevertheless, reports about the GI adverse effects of NSAIDs, especially on the lower gastrointestinal (GI) tract, and the detrimental function of their controlled release formulations continue to surface despite their COX selectivity. The GI sparing qualities of rofecoxib, a COXIB that has been discontinued due to cardiovascular (CV) adverse effects, are also called into question by previously disclosed data kept in the sponsor's files. GI problems, renal problems, and cardiovascular events are currently the main adverse effects of NSAIDs. There is a propensity to assume that all NSAIDs have negative effects on the kidneys and cardiovascular system, a notion that is not well-supported by data. In fact, several NSAIDs may have cardioprotective effects at lower but still therapeutic doses. These results imply that long-term NSAID use may hasten the transition to total knee replacement by significantly aggravating symptoms, while also accepting the limitations of this study due to its observational methodology and the possibility of bidirectional causality.
Keywords
Cyclooxygenase enzyme, cardiovascular adverse effects, bidirectional causality, anti-arthritic, analgesic, disadvantages.How to Cite
References
Ghlichloo I, Gerriets V. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547742/
Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O'Hanlon CE, Tariq A, Okunogbe A, Han D, Shanman R. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017 Jan 03;166(1):37-51.
Oyler DR, Parli SE, Bernard AC, Chang PK, Procter LD, Harned ME. Nonopioid management of acute pain associated with trauma: Focus on pharmacologic options. J Trauma Acute Care Surg. 2015 Sep;79(3):475-83.
Salis, Z., Sainsbury, A. Association of long-term use of non-steroidal anti-inflammatory drugs with knee osteoarthritis: a prospective multi-cohort study over 4-to-5 years. Sci Rep 14, 6593 (2024). https://doi.org/10.1038/s41598-024-56665-3
Cui, B. et al. Effects of medications on incidence and risk of knee and hip joint replacement in patients with osteoarthritis: A systematic review and meta-analysis. Adv. Rheumatol. 62(1), 22 (2022).
Perry, T. A. et al. Association between current medication use and progression of radiographic knee osteoarthritis: Data from the osteoarthritis initiative. Rheumatol. (Oxf.) 60(10), 4624–4632 (2021).
Simic, M. et al. Clinical risk factors associated with radiographic osteoarthritis progression among people with knee pain: A longitudinal study. Arthrit. Res. Ther. 23(1), 160 (2021).
Rausch Osthoff, A. K. et al. Effects of exercise and physical activity promotion: Meta-analysis informing the 2018 EULAR recommendations for physical activity in people with rheumatoid arthritis, spondyloarthritis and hip/knee osteoarthritis. RMD Open 4(2), e000713 (2018).
Nevitt, M. C., David T. F. & Gayle, L. The osteoarthritis initiative. In Protocol for the cohort study. National Institute of Arthritis, Musculoskeletal and Skin Diseases. V 1.1 6.21.06 (2023, accessed 11 Dec 2023). https://nda.nih.gov/static/docs/StudyDesignProtocolAndAppendices.pdf.
Ton, J. et al. PEER umbrella systematic review of systematic reviews: Management of osteoarthritis in primary care. Can. Fam. Phys. 66(3), e89–e98 (2020).
Osani, M. C. et al. Duration of symptom relief and early trajectory of adverse events for oral nonsteroidal antiinflammatory drugs in knee osteoarthritis: A systematic review and meta-analysis. Arthrit. Care Res. (Hobok.) 72(5), 641–651 (2020).
da Costa, B. R. et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: Network meta-analysis. BMJ 375, n2321 (2021).
Silverman, S. L. et al. Drug utilization, clinical and economic outcomes of patients with osteoarthritis of the hip and/or knee treated with long-term use of traditional NSAIDs, topical NSAIDs, and COX-2 inhibitors. Curr. Med. Res. Opin. 38(7), 1153–1166 (2022).
Arden, N. K. et al. Non-surgical management of knee osteoarthritis: Comparison of ESCEO and OARSI 2019 guidelines. Nat. Rev. Rheumatol. 17(1), 59–66 (2021).
Kolasinski, S. L. et al. 2019 American College of Rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthrit. Care Res. 72(2), 149–162 (2020).
Hopkins S, Yang V, Liew DFL. Choosing a nonsteroidal anti-inflammatory drug for pain. Aust Prescr 2025;48:139-44.https://doi.org/10.18773/austprescr.2025.032
Rainsford, K.D. (1987). Introduction and historical aspects of the side-effects of anti-inflammatory analgesic drugs. In: Rainsford, K.D., Velo, G.P. (eds) Side-Effects of Anti-Inflammatory Drugs. Inflammation and Drug Therapy Series, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-9772-7_1
Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med. 1998 Mar 30;104(3A):23S-29S; discussion 41S-42S. doi: 10.1016/s0002-9343(97)00207-6.
Gómez-Acebo, I., Dierssen-Sotos, T., de Pedro, M. et al. Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study. BMC Public Health 18, 1134 (2018). https://doi.org/10.1186/s12889-018-6019-z
Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 2023;82:19-34.
License
Copyright (c) 2025 Shakhlo Bakhtiyorovna Qakhkharova, Iroda Brodarovna Takhirova
This work is licensed under a Creative Commons Attribution 4.0 International License.
